Table of Content

1 Study Coverage
1.1 Anti-angiogenic Ophthalmic Agent Product Introduction
1.2 Market by Type
1.2.1 Global Anti-angiogenic Ophthalmic Agent Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Myopic Choroidal Neovascularization
1.2.3 Macular Edema
1.2.4 Diabetic Retinopathy
1.2.5 Macular Degeneration
1.3 Market by Application
1.3.1 Global Anti-angiogenic Ophthalmic Agent Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Retail Pharmacies
1.3.3 Online Pharmacies
1.3.4 Hospital Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Anti-angiogenic Ophthalmic Agent Sales Estimates and Forecasts 2018-2029
2.2 Global Anti-angiogenic Ophthalmic Agent Revenue by Region
2.2.1 Global Anti-angiogenic Ophthalmic Agent Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Anti-angiogenic Ophthalmic Agent Revenue by Region (2018-2024)
2.2.3 Global Anti-angiogenic Ophthalmic Agent Revenue by Region (2024-2029)
2.2.4 Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Region (2018-2029)
2.3 Global Anti-angiogenic Ophthalmic Agent Sales Estimates and Forecasts 2018-2029
2.4 Global Anti-angiogenic Ophthalmic Agent Sales by Region
2.4.1 Global Anti-angiogenic Ophthalmic Agent Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Anti-angiogenic Ophthalmic Agent Sales by Region (2018-2024)
2.4.3 Global Anti-angiogenic Ophthalmic Agent Sales by Region (2024-2029)
2.4.4 Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Anti-angiogenic Ophthalmic Agent Sales by Manufacturers
3.1.1 Global Anti-angiogenic Ophthalmic Agent Sales by Manufacturers (2018-2024)
3.1.2 Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Anti-angiogenic Ophthalmic Agent in 2022
3.2 Global Anti-angiogenic Ophthalmic Agent Revenue by Manufacturers
3.2.1 Global Anti-angiogenic Ophthalmic Agent Revenue by Manufacturers (2018-2024)
3.2.2 Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Anti-angiogenic Ophthalmic Agent Revenue in 2022
3.3 Global Key Players of Anti-angiogenic Ophthalmic Agent, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Anti-angiogenic Ophthalmic Agent Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Anti-angiogenic Ophthalmic Agent Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Anti-angiogenic Ophthalmic Agent, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Anti-angiogenic Ophthalmic Agent, Product Offered and Application
3.8 Global Key Manufacturers of Anti-angiogenic Ophthalmic Agent, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Anti-angiogenic Ophthalmic Agent Sales by Type
4.1.1 Global Anti-angiogenic Ophthalmic Agent Historical Sales by Type (2018-2024)
4.1.2 Global Anti-angiogenic Ophthalmic Agent Forecasted Sales by Type (2024-2029)
4.1.3 Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2018-2029)
4.2 Global Anti-angiogenic Ophthalmic Agent Revenue by Type
4.2.1 Global Anti-angiogenic Ophthalmic Agent Historical Revenue by Type (2018-2024)
4.2.2 Global Anti-angiogenic Ophthalmic Agent Forecasted Revenue by Type (2024-2029)
4.2.3 Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type (2018-2029)
4.3 Global Anti-angiogenic Ophthalmic Agent Price by Type
4.3.1 Global Anti-angiogenic Ophthalmic Agent Price by Type (2018-2024)
4.3.2 Global Anti-angiogenic Ophthalmic Agent Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Anti-angiogenic Ophthalmic Agent Sales by Application
5.1.1 Global Anti-angiogenic Ophthalmic Agent Historical Sales by Application (2018-2024)
5.1.2 Global Anti-angiogenic Ophthalmic Agent Forecasted Sales by Application (2024-2029)
5.1.3 Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Application (2018-2029)
5.2 Global Anti-angiogenic Ophthalmic Agent Revenue by Application
5.2.1 Global Anti-angiogenic Ophthalmic Agent Historical Revenue by Application (2018-2024)
5.2.2 Global Anti-angiogenic Ophthalmic Agent Forecasted Revenue by Application (2024-2029)
5.2.3 Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application (2018-2029)
5.3 Global Anti-angiogenic Ophthalmic Agent Price by Application
5.3.1 Global Anti-angiogenic Ophthalmic Agent Price by Application (2018-2024)
5.3.2 Global Anti-angiogenic Ophthalmic Agent Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Anti-angiogenic Ophthalmic Agent Market Size by Type
6.1.1 US & Canada Anti-angiogenic Ophthalmic Agent Sales by Type (2018-2029)
6.1.2 US & Canada Anti-angiogenic Ophthalmic Agent Revenue by Type (2018-2029)
6.2 US & Canada Anti-angiogenic Ophthalmic Agent Market Size by Application
6.2.1 US & Canada Anti-angiogenic Ophthalmic Agent Sales by Application (2018-2029)
6.2.2 US & Canada Anti-angiogenic Ophthalmic Agent Revenue by Application (2018-2029)
6.3 US & Canada Anti-angiogenic Ophthalmic Agent Market Size by Country
6.3.1 US & Canada Anti-angiogenic Ophthalmic Agent Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Anti-angiogenic Ophthalmic Agent Sales by Country (2018-2029)
6.3.3 US & Canada Anti-angiogenic Ophthalmic Agent Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Anti-angiogenic Ophthalmic Agent Market Size by Type
7.1.1 Europe Anti-angiogenic Ophthalmic Agent Sales by Type (2018-2029)
7.1.2 Europe Anti-angiogenic Ophthalmic Agent Revenue by Type (2018-2029)
7.2 Europe Anti-angiogenic Ophthalmic Agent Market Size by Application
7.2.1 Europe Anti-angiogenic Ophthalmic Agent Sales by Application (2018-2029)
7.2.2 Europe Anti-angiogenic Ophthalmic Agent Revenue by Application (2018-2029)
7.3 Europe Anti-angiogenic Ophthalmic Agent Market Size by Country
7.3.1 Europe Anti-angiogenic Ophthalmic Agent Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Anti-angiogenic Ophthalmic Agent Sales by Country (2018-2029)
7.3.3 Europe Anti-angiogenic Ophthalmic Agent Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Anti-angiogenic Ophthalmic Agent Market Size
8.1.1 China Anti-angiogenic Ophthalmic Agent Sales (2018-2029)
8.1.2 China Anti-angiogenic Ophthalmic Agent Revenue (2018-2029)
8.2 China Anti-angiogenic Ophthalmic Agent Market Size by Application
8.2.1 China Anti-angiogenic Ophthalmic Agent Sales by Application (2018-2029)
8.2.2 China Anti-angiogenic Ophthalmic Agent Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Anti-angiogenic Ophthalmic Agent Market Size by Type
9.1.1 Asia Anti-angiogenic Ophthalmic Agent Sales by Type (2018-2029)
9.1.2 Asia Anti-angiogenic Ophthalmic Agent Revenue by Type (2018-2029)
9.2 Asia Anti-angiogenic Ophthalmic Agent Market Size by Application
9.2.1 Asia Anti-angiogenic Ophthalmic Agent Sales by Application (2018-2029)
9.2.2 Asia Anti-angiogenic Ophthalmic Agent Revenue by Application (2018-2029)
9.3 Asia Anti-angiogenic Ophthalmic Agent Sales by Region
9.3.1 Asia Anti-angiogenic Ophthalmic Agent Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Anti-angiogenic Ophthalmic Agent Revenue by Region (2018-2029)
9.3.3 Asia Anti-angiogenic Ophthalmic Agent Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Market Size by Type
10.1.1 Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Market Size by Application
10.2.1 Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Sales by Country
10.3.1 Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Gilead Sciences, Inc.
11.1.1 Gilead Sciences, Inc. Company Information
11.1.2 Gilead Sciences, Inc. Overview
11.1.3 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Gilead Sciences, Inc. Recent Developments
11.2 Eyetech Inc.
11.2.1 Eyetech Inc. Company Information
11.2.2 Eyetech Inc. Overview
11.2.3 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Eyetech Inc. Recent Developments
11.3 Becton, Dickinson and Company
11.3.1 Becton, Dickinson and Company Company Information
11.3.2 Becton, Dickinson and Company Overview
11.3.3 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Becton, Dickinson and Company Recent Developments
11.4 Regeneron Pharmaceuticals, Inc.
11.4.1 Regeneron Pharmaceuticals, Inc. Company Information
11.4.2 Regeneron Pharmaceuticals, Inc. Overview
11.4.3 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Regeneron Pharmaceuticals, Inc. Recent Developments
11.5 Genentech, Inc.
11.5.1 Genentech, Inc. Company Information
11.5.2 Genentech, Inc. Overview
11.5.3 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Genentech, Inc. Recent Developments
11.6 Novartis AG
11.6.1 Novartis AG Company Information
11.6.2 Novartis AG Overview
11.6.3 Novartis AG Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Novartis AG Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Novartis AG Recent Developments
11.7 Allergan plc
11.7.1 Allergan plc Company Information
11.7.2 Allergan plc Overview
11.7.3 Allergan plc Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Allergan plc Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Allergan plc Recent Developments
11.8 Bayer AG
11.8.1 Bayer AG Company Information
11.8.2 Bayer AG Overview
11.8.3 Bayer AG Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Bayer AG Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Bayer AG Recent Developments
11.9 Santen Pharmaceutical Co., Ltd.
11.9.1 Santen Pharmaceutical Co., Ltd. Company Information
11.9.2 Santen Pharmaceutical Co., Ltd. Overview
11.9.3 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Santen Pharmaceutical Co., Ltd. Recent Developments
11.10 Shanghai Pharmaceuticals
11.10.1 Shanghai Pharmaceuticals Company Information
11.10.2 Shanghai Pharmaceuticals Overview
11.10.3 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Shanghai Pharmaceuticals Recent Developments
11.11 Johnson & Johnson
11.11.1 Johnson & Johnson Company Information
11.11.2 Johnson & Johnson Overview
11.11.3 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Johnson & Johnson Recent Developments
11.12 Pfizer
11.12.1 Pfizer Company Information
11.12.2 Pfizer Overview
11.12.3 Pfizer Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 Pfizer Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Pfizer Recent Developments
11.13 Sun Pharma
11.13.1 Sun Pharma Company Information
11.13.2 Sun Pharma Overview
11.13.3 Sun Pharma Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.13.4 Sun Pharma Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Sun Pharma Recent Developments
11.14 Otsuka Pharmaceutical Co. Ltd
11.14.1 Otsuka Pharmaceutical Co. Ltd Company Information
11.14.2 Otsuka Pharmaceutical Co. Ltd Overview
11.14.3 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.14.4 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Otsuka Pharmaceutical Co. Ltd Recent Developments
11.15 Daiichi Sankyo
11.15.1 Daiichi Sankyo Company Information
11.15.2 Daiichi Sankyo Overview
11.15.3 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.15.4 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Daiichi Sankyo Recent Developments
11.16 ERC Labs
11.16.1 ERC Labs Company Information
11.16.2 ERC Labs Overview
11.16.3 ERC Labs Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.16.4 ERC Labs Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 ERC Labs Recent Developments
11.17 Medicom Health care
11.17.1 Medicom Health care Company Information
11.17.2 Medicom Health care Overview
11.17.3 Medicom Health care Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.17.4 Medicom Health care Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Medicom Health care Recent Developments
11.18 Implant ophthalmic products GmbH
11.18.1 Implant ophthalmic products GmbH Company Information
11.18.2 Implant ophthalmic products GmbH Overview
11.18.3 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.18.4 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Implant ophthalmic products GmbH Recent Developments
11.19 The Geuder Group, MORCHER GmbH
11.19.1 The Geuder Group, MORCHER GmbH Company Information
11.19.2 The Geuder Group, MORCHER GmbH Overview
11.19.3 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.19.4 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 The Geuder Group, MORCHER GmbH Recent Developments
11.20 Novamedika
11.20.1 Novamedika Company Information
11.20.2 Novamedika Overview
11.20.3 Novamedika Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.20.4 Novamedika Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Novamedika Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Anti-angiogenic Ophthalmic Agent Industry Chain Analysis
12.2 Anti-angiogenic Ophthalmic Agent Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Anti-angiogenic Ophthalmic Agent Production Mode & Process
12.4 Anti-angiogenic Ophthalmic Agent Sales and Marketing
12.4.1 Anti-angiogenic Ophthalmic Agent Sales Channels
12.4.2 Anti-angiogenic Ophthalmic Agent Distributors
12.5 Anti-angiogenic Ophthalmic Agent Customers
13 Market Dynamics
13.1 Anti-angiogenic Ophthalmic Agent Industry Trends
13.2 Anti-angiogenic Ophthalmic Agent Market Drivers
13.3 Anti-angiogenic Ophthalmic Agent Market Challenges
13.4 Anti-angiogenic Ophthalmic Agent Market Restraints
14 Key Findings in The Global Anti-angiogenic Ophthalmic Agent Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Anti-angiogenic Ophthalmic Agent Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Myopic Choroidal Neovascularization
Table 3. Major Manufacturers of Macular Edema
Table 4. Major Manufacturers of Diabetic Retinopathy
Table 5. Major Manufacturers of Macular Degeneration
Table 6. Global Anti-angiogenic Ophthalmic Agent Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Anti-angiogenic Ophthalmic Agent Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 8. Global Anti-angiogenic Ophthalmic Agent Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Anti-angiogenic Ophthalmic Agent Revenue by Region (2024-2029) & (US$ Million)
Table 10. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Region (2018-2024)
Table 11. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Region (2024-2029)
Table 12. Global Anti-angiogenic Ophthalmic Agent Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 13. Global Anti-angiogenic Ophthalmic Agent Sales by Region (2018-2024) & (K Units)
Table 14. Global Anti-angiogenic Ophthalmic Agent Sales by Region (2024-2029) & (K Units)
Table 15. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Region (2018-2024)
Table 16. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Region (2024-2029)
Table 17. Global Anti-angiogenic Ophthalmic Agent Sales by Manufacturers (2018-2024) & (K Units)
Table 18. Global Anti-angiogenic Ophthalmic Agent Sales Share by Manufacturers (2018-2024)
Table 19. Global Anti-angiogenic Ophthalmic Agent Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Anti-angiogenic Ophthalmic Agent Revenue Share by Manufacturers (2018-2024)
Table 21. Global Key Players of Anti-angiogenic Ophthalmic Agent, Industry Ranking, 2021 VS 2022 VS 2024
Table 22. Anti-angiogenic Ophthalmic Agent Price by Manufacturers 2018-2024 (US$/Unit)
Table 23. Global Anti-angiogenic Ophthalmic Agent Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Anti-angiogenic Ophthalmic Agent by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-angiogenic Ophthalmic Agent as of 2022)
Table 25. Global Key Manufacturers of Anti-angiogenic Ophthalmic Agent, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Anti-angiogenic Ophthalmic Agent, Product Offered and Application
Table 27. Global Key Manufacturers of Anti-angiogenic Ophthalmic Agent, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Anti-angiogenic Ophthalmic Agent Sales by Type (2018-2024) & (K Units)
Table 30. Global Anti-angiogenic Ophthalmic Agent Sales by Type (2024-2029) & (K Units)
Table 31. Global Anti-angiogenic Ophthalmic Agent Sales Share by Type (2018-2024)
Table 32. Global Anti-angiogenic Ophthalmic Agent Sales Share by Type (2024-2029)
Table 33. Global Anti-angiogenic Ophthalmic Agent Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Anti-angiogenic Ophthalmic Agent Revenue by Type (2024-2029) & (US$ Million)
Table 35. Global Anti-angiogenic Ophthalmic Agent Revenue Share by Type (2018-2024)
Table 36. Global Anti-angiogenic Ophthalmic Agent Revenue Share by Type (2024-2029)
Table 37. Anti-angiogenic Ophthalmic Agent Price by Type (2018-2024) & (US$/Unit)
Table 38. Global Anti-angiogenic Ophthalmic Agent Price Forecast by Type (2024-2029) & (US$/Unit)
Table 39. Global Anti-angiogenic Ophthalmic Agent Sales by Application (2018-2024) & (K Units)
Table 40. Global Anti-angiogenic Ophthalmic Agent Sales by Application (2024-2029) & (K Units)
Table 41. Global Anti-angiogenic Ophthalmic Agent Sales Share by Application (2018-2024)
Table 42. Global Anti-angiogenic Ophthalmic Agent Sales Share by Application (2024-2029)
Table 43. Global Anti-angiogenic Ophthalmic Agent Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Anti-angiogenic Ophthalmic Agent Revenue by Application (2024-2029) & (US$ Million)
Table 45. Global Anti-angiogenic Ophthalmic Agent Revenue Share by Application (2018-2024)
Table 46. Global Anti-angiogenic Ophthalmic Agent Revenue Share by Application (2024-2029)
Table 47. Anti-angiogenic Ophthalmic Agent Price by Application (2018-2024) & (US$/Unit)
Table 48. Global Anti-angiogenic Ophthalmic Agent Price Forecast by Application (2024-2029) & (US$/Unit)
Table 49. US & Canada Anti-angiogenic Ophthalmic Agent Sales by Type (2018-2024) & (K Units)
Table 50. US & Canada Anti-angiogenic Ophthalmic Agent Sales by Type (2024-2029) & (K Units)
Table 51. US & Canada Anti-angiogenic Ophthalmic Agent Revenue by Type (2018-2024) & (US$ Million)
Table 52. US & Canada Anti-angiogenic Ophthalmic Agent Revenue by Type (2024-2029) & (US$ Million)
Table 53. US & Canada Anti-angiogenic Ophthalmic Agent Sales by Application (2018-2024) & (K Units)
Table 54. US & Canada Anti-angiogenic Ophthalmic Agent Sales by Application (2024-2029) & (K Units)
Table 55. US & Canada Anti-angiogenic Ophthalmic Agent Revenue by Application (2018-2024) & (US$ Million)
Table 56. US & Canada Anti-angiogenic Ophthalmic Agent Revenue by Application (2024-2029) & (US$ Million)
Table 57. US & Canada Anti-angiogenic Ophthalmic Agent Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 58. US & Canada Anti-angiogenic Ophthalmic Agent Revenue by Country (2018-2024) & (US$ Million)
Table 59. US & Canada Anti-angiogenic Ophthalmic Agent Revenue by Country (2024-2029) & (US$ Million)
Table 60. US & Canada Anti-angiogenic Ophthalmic Agent Sales by Country (2018-2024) & (K Units)
Table 61. US & Canada Anti-angiogenic Ophthalmic Agent Sales by Country (2024-2029) & (K Units)
Table 62. Europe Anti-angiogenic Ophthalmic Agent Sales by Type (2018-2024) & (K Units)
Table 63. Europe Anti-angiogenic Ophthalmic Agent Sales by Type (2024-2029) & (K Units)
Table 64. Europe Anti-angiogenic Ophthalmic Agent Revenue by Type (2018-2024) & (US$ Million)
Table 65. Europe Anti-angiogenic Ophthalmic Agent Revenue by Type (2024-2029) & (US$ Million)
Table 66. Europe Anti-angiogenic Ophthalmic Agent Sales by Application (2018-2024) & (K Units)
Table 67. Europe Anti-angiogenic Ophthalmic Agent Sales by Application (2024-2029) & (K Units)
Table 68. Europe Anti-angiogenic Ophthalmic Agent Revenue by Application (2018-2024) & (US$ Million)
Table 69. Europe Anti-angiogenic Ophthalmic Agent Revenue by Application (2024-2029) & (US$ Million)
Table 70. Europe Anti-angiogenic Ophthalmic Agent Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 71. Europe Anti-angiogenic Ophthalmic Agent Revenue by Country (2018-2024) & (US$ Million)
Table 72. Europe Anti-angiogenic Ophthalmic Agent Revenue by Country (2024-2029) & (US$ Million)
Table 73. Europe Anti-angiogenic Ophthalmic Agent Sales by Country (2018-2024) & (K Units)
Table 74. Europe Anti-angiogenic Ophthalmic Agent Sales by Country (2024-2029) & (K Units)
Table 75. China Anti-angiogenic Ophthalmic Agent Sales by Type (2018-2024) & (K Units)
Table 76. China Anti-angiogenic Ophthalmic Agent Sales by Type (2024-2029) & (K Units)
Table 77. China Anti-angiogenic Ophthalmic Agent Revenue by Type (2018-2024) & (US$ Million)
Table 78. China Anti-angiogenic Ophthalmic Agent Revenue by Type (2024-2029) & (US$ Million)
Table 79. China Anti-angiogenic Ophthalmic Agent Sales by Application (2018-2024) & (K Units)
Table 80. China Anti-angiogenic Ophthalmic Agent Sales by Application (2024-2029) & (K Units)
Table 81. China Anti-angiogenic Ophthalmic Agent Revenue by Application (2018-2024) & (US$ Million)
Table 82. China Anti-angiogenic Ophthalmic Agent Revenue by Application (2024-2029) & (US$ Million)
Table 83. Asia Anti-angiogenic Ophthalmic Agent Sales by Type (2018-2024) & (K Units)
Table 84. Asia Anti-angiogenic Ophthalmic Agent Sales by Type (2024-2029) & (K Units)
Table 85. Asia Anti-angiogenic Ophthalmic Agent Revenue by Type (2018-2024) & (US$ Million)
Table 86. Asia Anti-angiogenic Ophthalmic Agent Revenue by Type (2024-2029) & (US$ Million)
Table 87. Asia Anti-angiogenic Ophthalmic Agent Sales by Application (2018-2024) & (K Units)
Table 88. Asia Anti-angiogenic Ophthalmic Agent Sales by Application (2024-2029) & (K Units)
Table 89. Asia Anti-angiogenic Ophthalmic Agent Revenue by Application (2018-2024) & (US$ Million)
Table 90. Asia Anti-angiogenic Ophthalmic Agent Revenue by Application (2024-2029) & (US$ Million)
Table 91. Asia Anti-angiogenic Ophthalmic Agent Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 92. Asia Anti-angiogenic Ophthalmic Agent Revenue by Region (2018-2024) & (US$ Million)
Table 93. Asia Anti-angiogenic Ophthalmic Agent Revenue by Region (2024-2029) & (US$ Million)
Table 94. Asia Anti-angiogenic Ophthalmic Agent Sales by Region (2018-2024) & (K Units)
Table 95. Asia Anti-angiogenic Ophthalmic Agent Sales by Region (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Sales by Type (2018-2024) & (K Units)
Table 97. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Sales by Type (2024-2029) & (K Units)
Table 98. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Revenue by Type (2018-2024) & (US$ Million)
Table 99. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Revenue by Type (2024-2029) & (US$ Million)
Table 100. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Sales by Application (2018-2024) & (K Units)
Table 101. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Sales by Application (2024-2029) & (K Units)
Table 102. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Revenue by Application (2018-2024) & (US$ Million)
Table 103. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Revenue by Application (2024-2029) & (US$ Million)
Table 104. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 105. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Revenue by Country (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Revenue by Country (2024-2029) & (US$ Million)
Table 107. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Sales by Country (2018-2024) & (K Units)
Table 108. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Sales by Country (2024-2029) & (K Units)
Table 109. Gilead Sciences, Inc. Company Information
Table 110. Gilead Sciences, Inc. Description and Major Businesses
Table 111. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 112. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. Gilead Sciences, Inc. Recent Developments
Table 114. Eyetech Inc. Company Information
Table 115. Eyetech Inc. Description and Major Businesses
Table 116. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 117. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. Eyetech Inc. Recent Developments
Table 119. Becton, Dickinson and Company Company Information
Table 120. Becton, Dickinson and Company Description and Major Businesses
Table 121. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 122. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. Becton, Dickinson and Company Recent Developments
Table 124. Regeneron Pharmaceuticals, Inc. Company Information
Table 125. Regeneron Pharmaceuticals, Inc. Description and Major Businesses
Table 126. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 127. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 128. Regeneron Pharmaceuticals, Inc. Recent Developments
Table 129. Genentech, Inc. Company Information
Table 130. Genentech, Inc. Description and Major Businesses
Table 131. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 132. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 133. Genentech, Inc. Recent Developments
Table 134. Novartis AG Company Information
Table 135. Novartis AG Description and Major Businesses
Table 136. Novartis AG Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 137. Novartis AG Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 138. Novartis AG Recent Developments
Table 139. Allergan plc Company Information
Table 140. Allergan plc Description and Major Businesses
Table 141. Allergan plc Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 142. Allergan plc Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 143. Allergan plc Recent Developments
Table 144. Bayer AG Company Information
Table 145. Bayer AG Description and Major Businesses
Table 146. Bayer AG Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 147. Bayer AG Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 148. Bayer AG Recent Developments
Table 149. Santen Pharmaceutical Co., Ltd. Company Information
Table 150. Santen Pharmaceutical Co., Ltd. Description and Major Businesses
Table 151. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 152. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 153. Santen Pharmaceutical Co., Ltd. Recent Developments
Table 154. Shanghai Pharmaceuticals Company Information
Table 155. Shanghai Pharmaceuticals Description and Major Businesses
Table 156. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 157. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 158. Shanghai Pharmaceuticals Recent Developments
Table 159. Johnson & Johnson Company Information
Table 160. Johnson & Johnson Description and Major Businesses
Table 161. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 162. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 163. Johnson & Johnson Recent Developments
Table 164. Pfizer Company Information
Table 165. Pfizer Description and Major Businesses
Table 166. Pfizer Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 167. Pfizer Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 168. Pfizer Recent Developments
Table 169. Sun Pharma Company Information
Table 170. Sun Pharma Description and Major Businesses
Table 171. Sun Pharma Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 172. Sun Pharma Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 173. Sun Pharma Recent Developments
Table 174. Otsuka Pharmaceutical Co. Ltd Company Information
Table 175. Otsuka Pharmaceutical Co. Ltd Description and Major Businesses
Table 176. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 177. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 178. Otsuka Pharmaceutical Co. Ltd Recent Developments
Table 179. Daiichi Sankyo Company Information
Table 180. Daiichi Sankyo Description and Major Businesses
Table 181. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 182. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 183. Daiichi Sankyo Recent Developments
Table 184. ERC Labs Company Information
Table 185. ERC Labs Description and Major Businesses
Table 186. ERC Labs Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 187. ERC Labs Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 188. ERC Labs Recent Developments
Table 189. Medicom Health care Company Information
Table 190. Medicom Health care Description and Major Businesses
Table 191. Medicom Health care Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 192. Medicom Health care Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 193. Medicom Health care Recent Developments
Table 194. Implant ophthalmic products GmbH Company Information
Table 195. Implant ophthalmic products GmbH Description and Major Businesses
Table 196. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 197. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 198. Implant ophthalmic products GmbH Recent Developments
Table 199. The Geuder Group, MORCHER GmbH Company Information
Table 200. The Geuder Group, MORCHER GmbH Description and Major Businesses
Table 201. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 202. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 203. The Geuder Group, MORCHER GmbH Recent Developments
Table 204. Novamedika Company Information
Table 205. Novamedika Description and Major Businesses
Table 206. Novamedika Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 207. Novamedika Anti-angiogenic Ophthalmic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 208. Novamedika Recent Developments
Table 209. Key Raw Materials Lists
Table 210. Raw Materials Key Suppliers Lists
Table 211. Anti-angiogenic Ophthalmic Agent Distributors List
Table 212. Anti-angiogenic Ophthalmic Agent Customers List
Table 213. Anti-angiogenic Ophthalmic Agent Market Trends
Table 214. Anti-angiogenic Ophthalmic Agent Market Drivers
Table 215. Anti-angiogenic Ophthalmic Agent Market Challenges
Table 216. Anti-angiogenic Ophthalmic Agent Market Restraints
Table 217. Research Programs/Design for This Report
Table 218. Key Data Information from Secondary Sources
Table 219. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-angiogenic Ophthalmic Agent Product Picture
Figure 2. Global Anti-angiogenic Ophthalmic Agent Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Anti-angiogenic Ophthalmic Agent Market Share by Type in 2022 & 2029
Figure 4. Myopic Choroidal Neovascularization Product Picture
Figure 5. Macular Edema Product Picture
Figure 6. Diabetic Retinopathy Product Picture
Figure 7. Macular Degeneration Product Picture
Figure 8. Global Anti-angiogenic Ophthalmic Agent Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global Anti-angiogenic Ophthalmic Agent Market Share by Application in 2022 & 2029
Figure 10. Retail Pharmacies
Figure 11. Online Pharmacies
Figure 12. Hospital Pharmacies
Figure 13. Anti-angiogenic Ophthalmic Agent Report Years Considered
Figure 14. Global Anti-angiogenic Ophthalmic Agent Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Anti-angiogenic Ophthalmic Agent Revenue 2018-2029 (US$ Million)
Figure 16. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 17. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Region (2018-2029)
Figure 18. Global Anti-angiogenic Ophthalmic Agent Sales 2018-2029 ((K Units)
Figure 19. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Region (2018-2029)
Figure 20. US & Canada Anti-angiogenic Ophthalmic Agent Sales YoY (2018-2029) & (K Units)
Figure 21. US & Canada Anti-angiogenic Ophthalmic Agent Revenue YoY (2018-2029) & (US$ Million)
Figure 22. Europe Anti-angiogenic Ophthalmic Agent Sales YoY (2018-2029) & (K Units)
Figure 23. Europe Anti-angiogenic Ophthalmic Agent Revenue YoY (2018-2029) & (US$ Million)
Figure 24. China Anti-angiogenic Ophthalmic Agent Sales YoY (2018-2029) & (K Units)
Figure 25. China Anti-angiogenic Ophthalmic Agent Revenue YoY (2018-2029) & (US$ Million)
Figure 26. Asia (excluding China) Anti-angiogenic Ophthalmic Agent Sales YoY (2018-2029) & (K Units)
Figure 27. Asia (excluding China) Anti-angiogenic Ophthalmic Agent Revenue YoY (2018-2029) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Sales YoY (2018-2029) & (K Units)
Figure 29. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Revenue YoY (2018-2029) & (US$ Million)
Figure 30. The Anti-angiogenic Ophthalmic Agent Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 31. The Top 5 and 10 Largest Manufacturers of Anti-angiogenic Ophthalmic Agent in the World: Market Share by Anti-angiogenic Ophthalmic Agent Revenue in 2022
Figure 32. Global Anti-angiogenic Ophthalmic Agent Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2018-2029)
Figure 34. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type (2018-2029)
Figure 35. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Application (2018-2029)
Figure 36. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application (2018-2029)
Figure 37. US & Canada Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2018-2029)
Figure 38. US & Canada Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type (2018-2029)
Figure 39. US & Canada Anti-angiogenic Ophthalmic Agent Sales Market Share by Application (2018-2029)
Figure 40. US & Canada Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application (2018-2029)
Figure 41. US & Canada Anti-angiogenic Ophthalmic Agent Revenue Share by Country (2018-2029)
Figure 42. US & Canada Anti-angiogenic Ophthalmic Agent Sales Share by Country (2018-2029)
Figure 43. U.S. Anti-angiogenic Ophthalmic Agent Revenue (2018-2029) & (US$ Million)
Figure 44. Canada Anti-angiogenic Ophthalmic Agent Revenue (2018-2029) & (US$ Million)
Figure 45. Europe Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2018-2029)
Figure 46. Europe Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type (2018-2029)
Figure 47. Europe Anti-angiogenic Ophthalmic Agent Sales Market Share by Application (2018-2029)
Figure 48. Europe Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application (2018-2029)
Figure 49. Europe Anti-angiogenic Ophthalmic Agent Revenue Share by Country (2018-2029)
Figure 50. Europe Anti-angiogenic Ophthalmic Agent Sales Share by Country (2018-2029)
Figure 51. Germany Anti-angiogenic Ophthalmic Agent Revenue (2018-2029) & (US$ Million)
Figure 52. France Anti-angiogenic Ophthalmic Agent Revenue (2018-2029) & (US$ Million)
Figure 53. U.K. Anti-angiogenic Ophthalmic Agent Revenue (2018-2029) & (US$ Million)
Figure 54. Italy Anti-angiogenic Ophthalmic Agent Revenue (2018-2029) & (US$ Million)
Figure 55. Russia Anti-angiogenic Ophthalmic Agent Revenue (2018-2029) & (US$ Million)
Figure 56. China Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2018-2029)
Figure 57. China Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type (2018-2029)
Figure 58. China Anti-angiogenic Ophthalmic Agent Sales Market Share by Application (2018-2029)
Figure 59. China Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application (2018-2029)
Figure 60. Asia Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2018-2029)
Figure 61. Asia Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type (2018-2029)
Figure 62. Asia Anti-angiogenic Ophthalmic Agent Sales Market Share by Application (2018-2029)
Figure 63. Asia Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application (2018-2029)
Figure 64. Asia Anti-angiogenic Ophthalmic Agent Revenue Share by Region (2018-2029)
Figure 65. Asia Anti-angiogenic Ophthalmic Agent Sales Share by Region (2018-2029)
Figure 66. Japan Anti-angiogenic Ophthalmic Agent Revenue (2018-2029) & (US$ Million)
Figure 67. South Korea Anti-angiogenic Ophthalmic Agent Revenue (2018-2029) & (US$ Million)
Figure 68. China Taiwan Anti-angiogenic Ophthalmic Agent Revenue (2018-2029) & (US$ Million)
Figure 69. Southeast Asia Anti-angiogenic Ophthalmic Agent Revenue (2018-2029) & (US$ Million)
Figure 70. India Anti-angiogenic Ophthalmic Agent Revenue (2018-2029) & (US$ Million)
Figure 71. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2018-2029)
Figure 72. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type (2018-2029)
Figure 73. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Sales Market Share by Application (2018-2029)
Figure 74. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application (2018-2029)
Figure 75. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Revenue Share by Country (2018-2029)
Figure 76. Middle East, Africa and Latin America Anti-angiogenic Ophthalmic Agent Sales Share by Country (2018-2029)
Figure 77. Brazil Anti-angiogenic Ophthalmic Agent Revenue (2018-2029) & (US$ Million)
Figure 78. Mexico Anti-angiogenic Ophthalmic Agent Revenue (2018-2029) & (US$ Million)
Figure 79. Turkey Anti-angiogenic Ophthalmic Agent Revenue (2018-2029) & (US$ Million)
Figure 80. Israel Anti-angiogenic Ophthalmic Agent Revenue (2018-2029) & (US$ Million)
Figure 81. GCC Countries Anti-angiogenic Ophthalmic Agent Revenue (2018-2029) & (US$ Million)
Figure 82. Anti-angiogenic Ophthalmic Agent Value Chain
Figure 83. Anti-angiogenic Ophthalmic Agent Production Process
Figure 84. Channels of Distribution
Figure 85. Distributors Profiles
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed